Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2024 | Amyloidosis Sessions: Highlights from ASH 2024

Ashutosh Wechalekar and Vaishali Sanchorawala • 8 Dec 2024
ASH 2024
Amyloidosis Rare Diseases Antibodies Bortezomib CAR-T Cyclophosphamide Daratumumab Dexamethasone NXC-201
ANDROMEDA

Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematology and Hematological Oncology (VJHemOnc). This exclusive session features experts Vaishali Sanchorawala and Ashutosh Wechalekar, who discuss their highlights in amyloidosis presented at the 2024 ASH Annual Meeting and Exposition. The experts cover several topics, including updates from the ANDROMEDA trial (NCT03201965), the risk stratification of patients with light chain (AL) amyloidosis, the value of measurable residual disease (MRD), and potential advances with CAR T-cell therapy in this disease setting.

More from Ashutosh Wechalekar

Advances in the treatment and diagnosis of amyloidosis: what does the future hold?
1:36
Advances in the treatment and diagnosis of amyloidosis: what does the future hold?
Ashutosh Wechalekar et al. • 13 Jun 2025
Treatment strategies for patients with R/R amyloidosis: targeting BCL2 or BCMA
1:34
Treatment strategies for patients with R/R amyloidosis: targeting BCL2 or BCMA
Ashutosh Wechalekar et al. • 13 Jun 2025
Hidden light chain amyloidosis in patients with multiple myeloma
1:45
Hidden light chain amyloidosis in patients with multiple myeloma
Ashutosh Wechalekar et al. • 13 Jun 2025
Results of the Phase III AFFIRM-AL trial of birtamimab in AL amyloidosis
1:12
Results of the Phase III AFFIRM-AL trial of birtamimab in AL amyloidosis
Ashutosh Wechalekar et al. • 14 Jun 2025

More from Vaishali Sanchorawala

Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Ashutosh Wechalekar et al. • 8 Dec 2025
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
5:43
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
Ashutosh Wechalekar et al. • 8 Dec 2025
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
1:03
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
Ashutosh Wechalekar et al. • 8 Dec 2025
Amyloidosis Sessions: Highlights from ISA 2022
Amyloidosis Sessions: Highlights from ISA 2022
Ashutosh Wechalekar et al. • 6 Sep 2022

Related Videos

Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Ashutosh Wechalekar et al. • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Ashutosh Wechalekar et al. • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Ashutosh Wechalekar et al. • 8 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Ashutosh Wechalekar et al. • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals